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PCV13 whereas it was associated with an incremental cost of approximately £9
million vs. NoVac. PPV23 dominated PCV13 from both the third-party payer (TPP)
and the societal perspectives. When compared to NoVac, the incremental CE ratio
(ICER) was estimated at £14,813 and £13,497/QALY gained, from the TPP and the
societal perspective, respectively. CONCLUSIONS: The model suggests that vacci-
nating with PPV23 is cost-effective when compared to both PCV13 and NoVac. As
PPV23 covers 80%-90% of all serotypes causing IPD, it is still cost-effective despite
the recent reduction in IPD incidence in adults. The assumptions around the effi-
cacy of PCV13 are a substantial source of uncertainty.
PIN65
COST-EFFECTIVENESS OF FIRST-LINE ANTIRETROVIRAL REGIMENS FOR
HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN COLOMBIA: AN ANALYSIS OF
LOPINAVIR/RITONAVIR (LPV/R) AND DARUNAVIR PLUS RITONAVIR (DRVRTV)
IN TREATMENT-NAÏVE PATIENTS
Moller J1, Desai K2, Simpson KN3, Baran R4, Dietz B5, Van de Steen O6
1United BioSource Corporation, Eslov, Sweden, 2United BioSource Corporation, London, UK,
3Medical University of South Carolina, Charleston, SC, USA, 4Abbott Laboratories, Abbott Park,
IL, USA, 5Abbott GmbH & Co. KG, Ludwigshafen, Germany, 6Abbott Laboratories, Wavre, IL,
Belgium
OBJECTIVES: Current antiretroviral (ARV) therapy has transformed HIV from an
acute to a chronic disease. Consequently, there are more patients living with HIV
and the cost burden to societies that provide lifetime health care, such as Colom-
bia, is increasing. The value assessment of ARV regimens, therefore, requires a
lifetime horizon to accommodate implications of failure, resistance, switching and
survival. The objective was to perform a cost-effectiveness analysis of two first-line
protease inhibitor-based regimens for HIV-infected, ARV-naïve patients in Colom-
bia: LPV/r versus DRVRTV.METHODS:A previously published discrete event sim-
ulation model of first-line LPV/r and DRVRTV was adapted to comprehensively
represent HIV management in Colombia. The impact of initial treatment on CD4
cell count, viral load, adherence, virologic suppression/failure/rebound, acquired
resistance, and ensuing treatment changes were based on ARTEMIS trial data and
the clinical literature. Up to 3 regimen changes were permitted over the model’s
lifetime horizon. Cardiovascular risk was based on the Framingham risk score.
Clinical measures included AIDS related and non-AIDS related events, AEs, time on
sequential therapies, and cardiovascular events. Outcomes included lifetime costs
and quality adjusted life years (QALYs), discounted at 3% per annum. Perspective
was the Colombian national health care system. Costs for ARVs and medical man-
agement were referenced to Colombia pesos (COP). RESULTS: Initiating LPV/r over
DRVRTV saved COP7,845,894 per patient over a lifetime with similar life expec-
tancy (0.02 years; -0.03 QALYs). Similar rates of death, AIDS events, cancer, and
lipoatrophy/lipodystrophy were predicted for both groups. Lifetime cost of cardio-
vascular events were COP70,020 per patient less in the LPV/r arm. LPV/r was cost
saving at 5 years (COP11,311,677) and was cost-effective across multiple sensitivity
analyses. CONCLUSIONS: Initiating HIV infected, ARV-naïve patients on a LPV/r-
based regimen compared to a DRVRTV-based regimen is cost saving and provides
similar life expectancy. Sensitivity analyses provided confidence around these
point estimates.
PIN66
COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13)
AND 23-VALENT (PPV23) PNEUMOCOCCAL VACCINES FOR SENIOR ADULTS IN
SÃO PAULO STATE, BRAZIL – PUBLIC PERSPECTIVE
Fujii RK1, Roberts CS2, Mould J2, Presa J3, Jardim E3, Manfrin DF4
1Pfizer, Inc., São Paulo, São Paulo, Brazil, 2Pfizer, New York, NY, USA, 3Pfizer Parmaceutics Inc.,
São Paulo, São Paulo, Brazil, 4Pfizer, Inc., São Paulo, SP, Brazil
OBJECTIVES: To evaluate the cost effectiveness of vaccinating the Brazilian state of
São Paulo’s population 60 years of age and older with the 13-valent pneumococcal
conjugate vaccine (PCV13) in comparison to the 23-valent pneumococcal polysac-
charide vaccine (PPV23), each as a single dose, from the public payer perspective.
METHODS: In order to estimate the pneumococcal disease costs and impact over a
40-year time horizon period, including acute meningitis (AM), invasive pneumo-
coccal disease (IPD), hospitalized pneumonia (HP) and non-complicated pneumo-
nia (NCP), a patient-level microsimulation model simulating vaccination and out-
comes of one cohort of 4.768.202 individuals 60 years of age and older was adapted.
The probabilities and direct medical costs were extracted from literature review
and national databases, with costs presented in US$2011. The effectiveness mea-
sures were expressed as cases of pneumococcal diseases avoided, overall deaths
avoided, and life years (LYs) saved. Effectiveness of PCV13 was derived from studies
in children and adjusted for age and immune status in the elderly; PPV23 was
assumed not to impact pneumonia based on published meta-analyses. Probabilis-
tic sensitivity analyses were conducted considering key variables. Discount rate of
5% was applied. RESULTS: Vaccinating with PCV13 prevents 281 AM, 3.615 IPD,
56.284 HP, 31.553 NCP and 15.742 deaths, saving 90.596 LYs compared to PPV23.
Total costs including vaccination and medical costs resulted in US$14.449.125 less
for PCV13 compared to PCV23 (US$786.747.906 vs. US$772.298.781). The model
showed robustness through sensitivity analyses.CONCLUSIONS:The analysis sug-
gests that vaccinating adults with PCV13 in Brazil is cost-saving compared to
PPV23. The results in economic and disease burden are substantial and they sup-
port the decision making in favor of PCV13 for its high impact in public health.
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OBJECTIVES: The Brazilian National Immunization Program currently offers 10-
valent Pneumococcal Conjugated Vaccine (PCV10) to all children less than 5 years
of age for free. The current study was developed to compare the costs of PCV13
vaccination plus campaign for corporations, versus a hypothetical scenario where
the corporation would incur in the expenditures to do the campaign as proposed
for PCV13 while vaccinating with free PCV10 under the corporative payer
perspective. METHODS: A cost minimization analysis was developed considering
vaccination costs, campaign and health management costs, wage and productivity
loss from employee absence due to child disease and the vaccinations. Clinical
events were retrieved from Pepe et al 2009, absence days due to health events were
retrieved from the average hospitalization days from DATASUS 2012 and ambula-
tory use was limited to 1 absence day. Total employee absence days were halved
assuming a partner outside the company to take care of the sick child and to take
it to the vaccinations. Average wage was retrieved from the Brazilian Institute for
Geography and Statistics 2011 data (IBGE) and production was estimated from the
indicator ‘revenue generated by the employee’, from a market research developed
by Exame magazine in 2011 using IBGE and the Brazilian Central Bank data. The
base case considered a real scenario from a large corporation in Brazil. Values were
expressed in 2011USD. RESULTS: Independent campaign with zero cost PCV10 and
PCV13 vaccination plus campaign totaled 67,90USD and 114,65USD per employee
respectively. Productivity loss was estimated to be 879,07USD and 667,89USD per
employee for PCV10 and PCV13 respectively. Considering all evaluated costs,
PCV10 and PCV13 totaled 946,97USD and 782,54USD per employee respectively.
CONCLUSIONS: The PCV13 vaccination plus campaign initiative is estimated to
save costs (164,42USD/employee), when compared to developing an independent
campaign, mainly driven by productivity loss at the corporative payer perspective.
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OBJECTIVES: To provide an estimate of the treatment related costs of caspofungin
versus liposomal amphotericin B (L-AmB) in febrile, neutropenic patients with a
presumed fungal infection in the Netherlands. METHODS: : A cost-minimization
analysis (CMA) was conducted based on the results of a head-to-head randomized
clinical trial, in which caspofungin (70mg on day 1, 50mg daily thereafter) was
compared to liposomal amphotericin B (3-5mg/kg daily). The trial showed no sig-
nificant difference in success rates (adults: 33.9% for caspofungin and 33.7% for
L-AmB); therefore, the two drugs can be considered equally efficacious. Main as-
sumptions in the CMA were that no drug was spilled and that the difference in drug
administration costs was negligible and could therefore be ignored. The robustness
of the predicted cost-estimates was tested within several scenario analyses, in-
cluding an analysis in a paediatric population. RESULTS: In the base case analysis,
treatment with caspofungin resulted in cost savings of €6,564 per infected adult
patient; mainly due to lower drug acquisition costs. These savings increased to
€8,024 in a scenario analysis assuming that partly emptied vials will not be stored
and used for another administration (ie. spillage of drugs). An additional scenario
revealed that only at extreme average treatment durations of one drug, a cost
neutral result would be obtained. Comparing both drugs in a paediatric population,
incremental costs of caspofungin over L-AmB ranged from -€2,319 to€1,291 for an
average Dutch child aged 16 (weight 62kg; body surface area 1.725m2) and 2 (weight
12.5kg; body surface area 0.555m2) years old respectively. CONCLUSIONS: The
present analysis shows that treatment with caspofungin results in considerable
cost savings compared to L-AmB for the treatment of febrile, neutropenic adult
patients with a presumed fungal infection in the Netherlands. In pediatric patients
cost consequences are depending on body surface area.
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OBJECTIVES: Streptococcus pneumonia causes invasive pneumococcal diseases (IPD),
meningitis and bacteremia, and non-invasive diseases such as pneumonia and
acute otitis media (AOM), leading to high morbidity and mortality in infants and
elderly in Malaysia. To examine the health and economic impacts of routinely
vaccinating infants with 13-valent pneumococcal vaccine (PCV13) compared to
10-valent pneumococcal conjugate vaccine (PCV10) or no vaccine in Malaysia.
METHODS: A Markov model was adapted with local data to evaluate the potential
public health and economic impact of routine vaccination of infants with PCV10 or
PCV13 over a 10-year time horizon, assuming a 3-dose regimen at 2, 4, 12 months of
age and coverage of 90%. Direct effectiveness of PCV13 and PCV10 was estimated
from clinical trial data while indirect (herd) effectiveness was estimated from U.S.
surveillance data. Epidemiology, serotype coverage, and costs were from published
studies and government websites. One-way and multivariate probabilistic sensi-
tivity analyses were performed to test the robustness of model assumptions.
RESULTS: Compared to no vaccination, universal infant PCV13 vaccination would
avoid 19,833 cases of IPD, 832,687 and 1,705,984 cases of hospitalized and non-
hospitalized pneumonia respectively, and 135,675 cases of AOM with the preven-
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